Update 11th January 2026 RayzeBio has a new trial with the product RYZ401 entitled Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. Click here NCT07165132.  The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with … Continue reading Clinical Trials – Targeted Alpha-Emitter PRRT RYZ101 (Ac225)